Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT07842991
Recruiting Phase 3

Clinical Evaluation of a Toothpaste for Dental Plaque Reduction and Prevention of Gum Problems

NCT07842991 · tracked via the Priya Life Science Italy tracker
Phase
Phase 3
Started
2026-07-20
Last updated
2026-09-25

Condition(s) studied

PlaqueDental PlaqueGingivitis

Investigational drug(s) / intervention(s)

0.45% SnF HW with NaF (1450 F)67% Bicarbonate with NaF (1400 F)Colgate Cavity Protection Toothpaste →

0.45% SnF HW with NaF (1450 F): toothpaste

67% Bicarbonate with NaF (1400 F): toothpaste

Colgate Cavity Protection Toothpaste: Toothpaste with MFP/NaF (1450 F)

Study summary

Qualified subjects will be enrolled and randomized to either one of the three study groups described above based on their initial modified gingivitis and plaque scores. Subjects will be instructed to use the products according to the instructions provided. Subjects will return to the dental office for evaluation after three months and six months of product use. All subjects will be followed for adverse events throughout the study.

Eligibility

Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Subjects, ages 18-70, inclusive. * Availability for the six-month duration of the study. * Good general health. * Initial gingivitis index of at least 1.5 as determined by the use of the Modified Gingivitis Index. * Initial plaque index of at least 1.5 as determined by the use of the Modified Quigley-Hein Plaque Index. * Signed Informed Consent Form Exclusion Criteria: * Orthodontic bands. * Tumor(s) of the soft or hard tissues of the oral cavity. * Advanced periodontal disease (purulent exudate, tooth mobility), and/or * Extensive loss of periodontal attachment or alveolar bone. * Five or more carious lesions requiring immediate restorative treatment * Use of antibiotics any time during the one month prior to entry into the study. * Participation in any other clinical study or test panel within the one month prior to entry into the study. * Received a dental prophylaxis in the two weeks prior to your initial examination. * History of allergies to oral care/personal care consumer products or their ingredients. * Having taken any prescription medicines that might interfere with the study outcome. * If you with an existing medical condition which prohibits you from not eating or drinking for periods of up to 4 hours. * Self-reported pregnant or breast feeding an infant. * History of drug abuse

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Clinica Odontoiatrica Montesani Roma Rome Recruiting

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07842991 on ClinicalTrials.gov ↗ ← All trials in Italy